天津医药

• 论著 • 上一篇    下一篇

良性前列腺增生组织中CD8,CD20,IL-6和IL-23的表达

张伟1,韩瑞发2   

  1. 1. 天津医科大学第二医院泌尿外科C病区 刘利维转张伟收
    2. 天津市泌尿外科研究所
  • 收稿日期:2010-08-03 修回日期:2010-12-13 出版日期:2011-08-15 发布日期:2011-08-15
  • 通讯作者: 张伟

2   

  • Received:2010-08-03 Revised:2010-12-13 Published:2011-08-15 Online:2011-08-15

PDF (PC)

1926

摘要： 目的： 通过检测良性前列腺增生 (benign prostatic hyperplasia, BPH ) 患者手术标本中CD8,CD20,IL-6和IL-23的表达，探讨炎症免疫在BPH病因与进展中的作用。 方法： 收集60例BPH患者的临床资料及手术标本。采用免疫组化技术检测CD8,CD20,IL-6和IL-23在增生前列腺组织中的表达，将检测不同结果病例的临床数据进行对比性统计学分析。结果：CD8表达阳性49例(82%)，CD20表达阳性36例(60%)，IL-6表达阳性47例(78%),IL-23表达阳性33例(55%)。在检测指标全部强阳性病例组中，前列腺体积大于全部阴性的病例组，IPSS评分也更高（P<0.01）。 结论：BPH组织中存在着炎症细胞标志物和炎性因子的表达，并且与临床数据密切相关，提示炎症免疫可能在BPH的病因与进展中扮演了重要角色。

关键词: 良性前列腺增生, CD8, CD20, IL-6, IL-23

Abstract: Abstract Objective : Through detecting the expression of CD8,CD20, Interleukin-6 and Interleukin-23 in tissue of benign prostatic hyperplasia, evaluate the effect of immune-inflammation in the development and progression of BPH . Methods : Collect the medical records and specimens of 60 BPH patients treated by operation. Immunohistochemical analysis were used to examine the expression of CD8,CD20, Interleukin-6 and Interleukin-23 in BPH tissues. Results : 50 cases (83%) had CD8 as T-lymphocytes markers , 36 cases (60%) had CD20 as B-lymphocytes markers, 47cases(78%) had Interleukin-6 and 33 cases (55%) had Interleukin-23. The group of all cytokines are vivid positive had higher prostate volume and IPSS scores than the negative group (P<0.01). Conclusions : Inflammatory cell markers and inflammatory factors infiltrate the tissue of BPH,and had strong correlation with the clinical data. We can suppose that immune-inflammation may play an important role in the development and progression of BPH.

Key words: BPH, CD8, CD20, Interleukin-6, Interleukin-23.